Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous adipose-derived stem cell therapy for physical and oral frailty
jRCTb030260055Recruiting
- Sponsor
- Project for the Promotion of Infrastructure Development for the Practical Application of Regenerative Medicine
- Start
- Apr 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous adipose-derived mesenchymal stromal cells in Fragility and Oral Frailty (OF), sponsored by Project for the Promotion of Infrastructure Development for the Practical Application of Regenerative Medicine. Primary endpoint: Safety. Started Apr 2026; status: recruiting.
02
Drugs
autologous adipose-derived mesenchymal stromal cells
03
Conditions
FragilityOral Frailty (OF)
Beyond the preview
Go deeper on jRCTb030260055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTb030260055.